Advertisement
Advertise here Publish your press releases here Sponsor BioPortfolio
Follow us on Twitter Sign up for daily news and research emails Contributors wanted

Adocia re-acquires exclusive rights to insulin analog from US drug major

05:15 EDT 30 Jul 2013 | thePharmaLetter

French biotech firm Adocia (Euronext Paris: ADOC) has agreed with US pharma major Eli Lilly (NYSE: LLY) not to continue further joint research under the licensing agreement signed in December 2011 relating to use of Adocia's BioChaperone technology f...

Original Article: Adocia re-acquires exclusive rights to insulin analog from US drug major

NEXT ARTICLE

More From BioPortfolio on "Adocia re-acquires exclusive rights to insulin analog from US drug major"

Search BioPortfolio:
Advertisement
Advertisement

Searches Linking to this Story